Business
Inventiva to Participate in Upcoming September Investor Conferences
Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in the following upcoming investor events: H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday, Sept
About this update from Inventiva Sa
[{"type":"image","alt":"INVENTIVA","displaySize":"","headline":null,"caption":"INVENTIVA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":142,"url":"https://media.zenfs.com/en/globenewswire.com/fef5472de2e52c88120abbdb39dcd123"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IFR.Gz27ItPSlaHquTiPVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fef5472de2e52c88120abbdb39dcd123","width":300,"height":142}},"lazy":false},{"type":"text","content":"Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in the following upcoming investor events:","length":429,"tagName":"p"},{"type":"text","content":"H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday, September 9, 2025Time of the fireside chat: 3:00pm (EDT)/9:00pm (CEST)Location: New York, NY","length":166,"tagName":"p"},{"type":"text","content":"8th Edition of the Lyon Pôle Bourse ForumDate: Tuesday, September 23, 2025Location: Lyon, France","length":98,"tagName":"p"},{"type":"text","content":"KBC Life Sciences Conference Date: Thursday, September 25, 2025Time of the presentation: 5:00am (EDT)/11:00am (CEST)Location: Brussels, Belgium","length":151,"tagName":"p"},{"type":"text","content":"Stifel 2025 Virtual Cardiometabolic ForumDate: Tuesday, September 30, 2025Time of the presentation: 9:30am (EDT)/3:30pm (CEST)Location: Virtual","length":146,"tagName":"p"},{"type":"text","content":"European MIDCAP Event 2025Date: Tuesday, September 30 - Wednesday, October 1, 2025Location: Paris, France","length":109,"tagName":"p"},{"type":"text","content":"About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic...